We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $11.1B
1-Year Est. Return 207.82%
This Fund
S&P 500
This Quarter Est. Return
+52.07%
1 Year Est. Return
+207.82%
3 Year Est. Return
+512.05%
5 Year Est. Return
+1,035%
10 Year Est. Return
+45,230.58%
AUM
$7.74B
AUM Growth
+$2.03B
Cap. Flow
-$92.9M
Cap. Flow %
-1.2%
Top 10 Hldgs %
72.43%
Holding
35
New
5
Increased
11
Reduced
11
Closed
3

Top Buys

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$103M
2
GPCR icon
Structure Therapeutics
GPCR
+$103M
3
SLNO
Soleno Therapeutics
SLNO
+$39.1M
4
OCUL icon
Ocular Therapeutix
OCUL
+$34.1M
5
MRUS
Merus
MRUS
+$25.2M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$122M
2
UTHR icon
United Therapeutics
UTHR
+$117M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$112M
4
BPMC
Blueprint Medicines
BPMC
+$48.1M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$27.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.91%
2 Miscellaneous 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$17.7B
$1.02B 13.13%
5,110,000
+130,000
+3% +$24.2M
UTHR icon
2
United Therapeutics
UTHR
$20.9B
$848M 10.96%
2,022,222
-347,778
-15% -$117M
MDGL icon
3
Madrigal Pharmaceuticals
MDGL
$12.5B
$841M 10.87%
1,833,000
-42,000
-2% -$15.7M
ARGX icon
4
argenx
ARGX
$64.6B
$730M 9.44%
990,000
-185,000
-16% -$122M
KRYS icon
5
Krystal Biotech
KRYS
$10.6B
$490M 6.34%
2,777,777
+117,777
+4% +$17.6M
ARWR icon
6
Arrowhead Research
ARWR
$12.2B
$376M 4.86%
10,900,000
+300,000
+3% +$6.6M
KYMR icon
7
Kymera Therapeutics
KYMR
$9.76B
$359M 4.65%
6,350,000
-205,555
-3% -$9.27M
MRUS
8
DELISTED
Merus
MRUS
$334M 4.31%
3,542,500
+386,945
+12% +$25.2M
RNAM
9
DELISTED
Avidity Biosciences
RNAM
$333M 4.31%
7,645,000
+595,000
+8% +$24.1M
APLS
10
DELISTED
Apellis Pharmaceuticals
APLS
$277M 3.58%
12,222,222
– –
CNTA
11
DELISTED
Centessa Pharmaceuticals
CNTA
$262M 3.39%
10,808,080
+5,808,080
+116% +$103M
QURE icon
12
uniQure
QURE
$3.09B
$259M 3.35%
4,444,444
+819,444
+23% +$14.9M
XENE icon
13
Xenon Pharmaceuticals
XENE
$5.79B
$217M 2.8%
5,400,000
– –
AKRO
14
DELISTED
Akero Therapeutics
AKRO
$188M 2.43%
3,955,555
+455,555
+13% +$22.1M
VERA icon
15
Vera Therapeutics
VERA
$2.59B
$180M 2.33%
6,210,000
-90,000
-1% -$2.08M
SLNO
16
DELISTED
Soleno Therapeutics
SLNO
$174M 2.25%
2,577,777
+527,777
+26% +$39.1M
GPCR icon
17
Structure Therapeutics
GPCR
$3.38B
$144M 1.87%
+5,155,555
New +$103M
TRML
18
DELISTED
Tourmaline Bio
TRML
$122M 1.58%
2,555,555
– –
OCUL icon
19
Ocular Therapeutix
OCUL
$2.34B
$120M 1.55%
10,250,000
+2,850,000
+39% +$34.1M
FOLD
20
DELISTED
Amicus Therapeutics
FOLD
$118M 1.53%
15,025,000
-2,975,000
-17% -$21.2M
ETNB
21
DELISTED
89bio
ETNB
$93.9M 1.21%
6,387,790
-362,210
-5% -$3.69M
TSHA icon
22
Taysha Gene Therapies
TSHA
$1.82B
$71M 0.92%
21,700,000
– –
ALKS icon
23
Alkermes
ALKS
$7.73B
$67.2M 0.87%
2,240,000
-660,000
-23% -$18.6M
ORKA
24
Oruka Therapeutics
ORKA
$6.13B
$25.6M 0.33%
+1,333,340
New +$19.8M
SEPN
25
Septerna Inc
SEPN
$1.72B
$25.2M 0.33%
1,337,500
+100,000
+8% +$1.31M
1
2

Similar funds

GI
GAMCO Investors Greenwich, Connecticut $11.1B AUM 41.79% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
BEI
Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.05% 1-Year Est. Return
LCAM
London & Capital Asset Management London, United Kingdom $10.9B AUM 39.88% 1-Year Est. Return

Avoro Capital Advisors's Q3 2025 Portfolio in Review

As of Q3 2025, Avoro Capital Advisors held 35 positions worth $7.74B, up 35% from $5.71B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Avoro Capital Advisors's Q3 2025 filing shows 5 new, 11 increased, 11 reduced and 3 closed positions. Its largest new stake was Structure Therapeutics: 5,155,555 shares worth $144M. The largest sale was argenx, an estimated $122M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

  • Avoro Capital Advisors's largest Q3 2025 buy was Structure Therapeutics: 5,155,555 shares worth $144M.
  • Avoro Capital Advisors added most to Centessa Pharmaceuticals in Q3 2025, an estimated $103M increase.
  • Avoro Capital Advisors's biggest Q3 2025 reduction was argenx, cutting an estimated $122M.
  • Avoro Capital Advisors fully exited Blueprint Medicines in Q3 2025, selling an estimated $48.1M.
  • Avoro Capital Advisors's ten largest holdings make up 72% of its $7.74B portfolio in Q3 2025.
  • Avoro Capital Advisors opened 5 new positions and closed 3 in Q3 2025.
  • Avoro Capital Advisors's portfolio value rose 35% quarter-over-quarter to $7.74B.

Based on Avoro Capital Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.